




## **BK channel agonist represents a potential therapeutic approach for lysosomal storage diseases**

Xi Zoë Zhong<sup>1</sup>, Xue Sun<sup>1</sup>, Qi Cao<sup>1</sup>, Gaofeng Dong<sup>1</sup>, Raphael Schiffmann<sup>2</sup>, and Xian-Ping Dong<sup>1,\*</sup>

### **SUPPLEMENTARY FIGURES**

**Figure S1. Activation of BK reduces lipofuscin in NPC1 cells in a dose/time -dependent manner.** (A) Activation of BK with NS1619 (16 hrs) inhibited abnormal accumulation of lipofuscin (detected by autofluorescence) in NPC1 human fibroblasts in a dose-dependent manner. (B) Activation of BK with NS1619 (15  $\mu$ M) inhibited abnormal accumulation of lipofuscin in NPC1 human fibroblasts in a time-dependent manner. (C) Activation of BK with NS11021 (16 hrs) inhibited abnormal accumulation of lipofuscin in NPC1 human fibroblasts in a dose-dependent manner. More than 40 cells were analyzed for each condition.

**A****B****C****Figure S1**